Cargando…

Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders

Metabolic disorders are major clinical challenges of health that are progressing globally. A concurrence of metabolic disorders such as obesity, insulin resistance, atherogenic dyslipidemia, and systematic hypertension leads to metabolic syndrome. Over the past years, the metabolic syndrome leads to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Fang, Sun, Dong-Sheng, Wang, Kai-Li, Shang, Dan-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873594/
https://www.ncbi.nlm.nih.gov/pubmed/35223819
http://dx.doi.org/10.3389/fbioe.2021.811917
_version_ 1784657502770561024
author Hu, Fang
Sun, Dong-Sheng
Wang, Kai-Li
Shang, Dan-Ying
author_facet Hu, Fang
Sun, Dong-Sheng
Wang, Kai-Li
Shang, Dan-Ying
author_sort Hu, Fang
collection PubMed
description Metabolic disorders are major clinical challenges of health that are progressing globally. A concurrence of metabolic disorders such as obesity, insulin resistance, atherogenic dyslipidemia, and systematic hypertension leads to metabolic syndrome. Over the past years, the metabolic syndrome leads to a five- and two-fold rise in diabetes mellitus type II and cardiovascular diseases. Natural products specifically plant extracts have insulin-sensitizing, anti-inflammatory, and antioxidant properties and are also considered as an alternative option due to few adverse effects. Nanotechnology is one of the promising strategies, which improves the effectiveness of treatment and limits side effects. This review mainly focuses on plant extract-based nanosystems in the management of the metabolic syndrome. Numerous nano-drug delivery systems, i.e., liposomes, hydrogel nanocomposites, nanoemulsions, micelles, solid lipid, and core–shell nanoparticles, have been designed using plant extracts. It has been found that most of the nano-formulations successfully reduced oxidative stress, insulin resistance, chronic inflammation, and lipid profile in in vitro and in vivo studies as plant extracts interfere with the pathways of metabolic syndrome. Thus, these novel plant-based nanosystems could act as a promising candidate for clinical applications.
format Online
Article
Text
id pubmed-8873594
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88735942022-02-26 Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders Hu, Fang Sun, Dong-Sheng Wang, Kai-Li Shang, Dan-Ying Front Bioeng Biotechnol Bioengineering and Biotechnology Metabolic disorders are major clinical challenges of health that are progressing globally. A concurrence of metabolic disorders such as obesity, insulin resistance, atherogenic dyslipidemia, and systematic hypertension leads to metabolic syndrome. Over the past years, the metabolic syndrome leads to a five- and two-fold rise in diabetes mellitus type II and cardiovascular diseases. Natural products specifically plant extracts have insulin-sensitizing, anti-inflammatory, and antioxidant properties and are also considered as an alternative option due to few adverse effects. Nanotechnology is one of the promising strategies, which improves the effectiveness of treatment and limits side effects. This review mainly focuses on plant extract-based nanosystems in the management of the metabolic syndrome. Numerous nano-drug delivery systems, i.e., liposomes, hydrogel nanocomposites, nanoemulsions, micelles, solid lipid, and core–shell nanoparticles, have been designed using plant extracts. It has been found that most of the nano-formulations successfully reduced oxidative stress, insulin resistance, chronic inflammation, and lipid profile in in vitro and in vivo studies as plant extracts interfere with the pathways of metabolic syndrome. Thus, these novel plant-based nanosystems could act as a promising candidate for clinical applications. Frontiers Media S.A. 2022-02-11 /pmc/articles/PMC8873594/ /pubmed/35223819 http://dx.doi.org/10.3389/fbioe.2021.811917 Text en Copyright © 2022 Hu, Sun, Wang and Shang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Hu, Fang
Sun, Dong-Sheng
Wang, Kai-Li
Shang, Dan-Ying
Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders
title Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders
title_full Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders
title_fullStr Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders
title_full_unstemmed Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders
title_short Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders
title_sort nanomedicine of plant origin for the treatment of metabolic disorders
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873594/
https://www.ncbi.nlm.nih.gov/pubmed/35223819
http://dx.doi.org/10.3389/fbioe.2021.811917
work_keys_str_mv AT hufang nanomedicineofplantoriginforthetreatmentofmetabolicdisorders
AT sundongsheng nanomedicineofplantoriginforthetreatmentofmetabolicdisorders
AT wangkaili nanomedicineofplantoriginforthetreatmentofmetabolicdisorders
AT shangdanying nanomedicineofplantoriginforthetreatmentofmetabolicdisorders